Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B highlights several small-cap companies , including among the market's most expensive names based on valuation grades. Seeking Alpha's valuation grade compares how expensive or cheap a stock is relative to others in its specific sector. The score is calculated using a comprehensive combination of underlying valuation metrics—including P/E, PEG, EV/Sales, EV/EBITDA, EV/EBIT, Price/Sales, Price/Book, Price/Cash Flow, and dividend yield—factoring in both current and forward estimates. The overall valuation grade is derived from a comparison of all underlying metrics and reflects how attractively the stock is priced compared to its sector peers. Most expensive U.S. healthcare stock by valuation grade (market cap between $300M and $2B ): Biohaven ( BHVN ) : Valuation Grade F Greenwich LifeSciences ( GLSI ) : Valuation Grade F HealthStream ( HSTM ) : Valuation Grade F Immix Biopharma ( IMMX ) : Valuation Grade F IRADIMED CORPORATION ( IRMD ) : Valuation Grade F Mesa Laboratories ( MLAB ) : Valuation Grade F Sana Biotechnology ( SANA ) : Valuation Grade F SELLAS Life Sciences Group ( SLS ) : Valuation Grade F Savara ( SVRA ) : Valuation Grade F Trevi Therapeutics ( TRVI ) : Valuation Grade F More on Biohaven, Greenwich Lifesciences, etc. Sellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL Readout Biohaven: Despite Today's Gains, I Remain Skeptical Savara: The Rare Disease Funnel Is Becoming A Commercial Asset Immix Biopharma prices $150M stock offering at $8.94/share Immix rises after mid-stage trial data for AL amyloidosis therapy

格隆汇6月2日｜福布斯实时富豪榜单显示，软银集团创始人兼CEO孙正义身家攀升至1007亿美元，一举超越印度安巴尼、阿达尼等富豪，时隔十余年再度登顶亚洲首富宝座。

Why is AVGO up? GOOG's fundraising, Anthropic's IPO, Huang's Marvell call in focus Invezz

With major indices flirting with historically stretched valuations and inflation still nibbling at household budgets, dividend-paying stocks under $40 are getting a fresh look from retail investors who want income without overpaying for it. A sub-$40 entry point can be the difference between a position that earns its keep and one that locks up capital. ... 1 Legally Protected Monopoly Yielding Over 4% That Is Structurally Primed to Make Patient Investors Richer

In early trading on Tuesday, shares of Hewlett Packard Enterprise topped the list of the day's best performing components of the S&P 500 index, trading up 27.2%. Year to date, Hewlett Packard Enterprise Co registers a 149.0% gain. And the worst performing S&P 500 compo

The judgement, which was triggered by a case brought by the Attorney General for Northern Ireland, will apply across the UK.

Arrowhead Pharmaceuticals周二宣布，公司将参加6月举行的两场重要医疗健康会议，并在会上进行炉边谈话。届时管理层将分享公司在RNA干扰疗法领域的最新进展。 根据公司公告，Arrowhead将出席2026年杰富瑞全球医疗保健会议，时间为6月2日至4日，其中炉边谈话定于6月3日上午8时10分（美国东部时间）举行。另一场是6月8日至10日举办的 高盛 第47届全球医疗保健年会，炉边谈话安排在6月10日上午9时（美国东部时间）。两场会议的演示材料及网络直播链接均可通过Arrowhead官网投资者关系页面获取。 此次会议出席正值Arrowhead关键临床数据密集发布前夕。公司最受关注的催化剂是预计于第三季度公布的plozasiran治疗严重高甘油三酯血症的SHASTA-3和SHASTA-4研究数据。该药物作为一种预防胰腺炎的疗法被开发，若数据积极，美国市场销售峰值有望达到30亿至40亿美元。 在商业层面，Arrowhead首个商业化产品REDEMPLO在家族性乳糜微粒血症综合征的上市开局强劲。财报显示，该药自推出以来已开出超过400张处方，其中首个完整商业季度实现美国净销售额约100万美元。公司已将REDEMPLO的批发收购价从每年6万美元调整至4.5万美元，为未来向SHTG适应症扩展铺路。 其他重要催化剂包括：ARO-MAPT（针对阿尔茨海默病等tau蛋白病）预计在第三季度末或第四季度初报告脑脊液tau蛋白敲低数据；肥胖项目ARO-INHBE和ARO-ALK7将在下半年提供更多更新。 截至3月31日，Arrowhead拥有现金及投资总额约18亿美元，资金储备充足。 责任编辑：张俊 SF065

Tesla Sheds $75 Billion In Market Cap After Sam Altman Targets Optimus Benzinga

Why is AVGO up? GOOG's fundraising, Anthropic's IPO, Huang's Marvell call in focus MSN

Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Suncor Energy Inc (Symbol: SU) will trade ex-dividend, for its quarterly dividend of $0.60, payable on 6/25/26. As a percentage of SU's recent stock price of $64.55, this dividend works out to approximat

BING-JHEN HONG/iStock Editorial via Getty Images Investment Thesis The month of June 2026 is shaping up to be an interesting one for Nvidia Corporation ( NVDA ), with a unique paradox emerging around the company’s stock. For one thing, Nvidia is the clear leader in the AI industry, solidifying its top spot with an astronomical market cap of $5.1 trillion. Plus, a few days ago, CEO Jensen Huang shared some exciting news with the market about plans to enter the PC market with RTX Spark chips. But on the other hand, skeptics keep making bold claims more than ever, defending the idea that the AI bubble is about to burst. The result is two camps of irreconcilable sides, whose questions revolve around the hyperscalers’ CapEx cycle. Currently, there is a lot of skepticism in the market, with concerns about whether the growth in CapEx spending by IT giants will lead to unjustified multi-billion-dollar expenditures, since the monetization of AI agents may turn out to be considerably worse than that of traditional software. Moreover, current conditions are exacerbated by the geopolitical agenda, including ongoing conflict surrounding Iran, resulting in high oil prices that are fueling rising inflation expectations. A scenario of potential macroeconomic collapse, further escalation of military conflict, short-term market volatility, all obscure the main fundamental truth. Inertia of fear amplifies irrational investor thinking, leading them to overlook Blackwell’s pre-sales, whereas the order backlog projects $1 trillion in revenue by 2027. I regret to disappoint those investors who are selling NVDA shares based on market overheating concerns. Anything that might happen in the foreseeable future to drive down the company’s market value will be a rare gift, and not for sellers, rather for buyers who will benefit in the long run from the real scale of the economic transformation driven by AI. NVDA’s Growth Drivers Despite Record Market Capitalization Nvidia’s strategy is built ar...

BING-JHEN HONG/iStock Editorial via Getty Images Investment Thesis The month of June 2026 is shaping up to be an interesting one for Nvidia Corporation ( NVDA ), with a unique paradox emerging around the company’s stock. For one thing, Nvidia is the clear leader in the AI industry, solidifying its top spot with an astronomical market cap of $5.1 trillion. Plus, a few days ago, CEO Jensen Huang shared some exciting news with the market about plans to enter the PC market with RTX Spark chips. But on the other hand, skeptics keep making bold claims more than ever, defending the idea that the AI bubble is about to burst. The result is two camps of irreconcilable sides, whose questions revolve around the hyperscalers’ CapEx cycle. Currently, there is a lot of skepticism in the market, with concerns about whether the growth in CapEx spending by IT giants will lead to unjustified multi-billion-dollar expenditures, since the monetization of AI agents may turn out to be considerably worse than that of traditional software. Moreover, current conditions are exacerbated by the geopolitical agenda, including ongoing conflict surrounding Iran, resulting in high oil prices that are fueling rising inflation expectations. A scenario of potential macroeconomic collapse, further escalation of military conflict, and short-term market volatility all obscure the main fundamental truth. Inertia of fear amplifies irrational investor thinking, leading them to overlook Blackwell’s pre-sales, whereas the order backlog projects $1 trillion in revenue by 2027. I regret to disappoint those investors who are selling NVDA shares based on market overheating concerns. Anything that might happen in the foreseeable future to drive down the company’s market value will be a rare gift, and not for sellers, but rather for buyers who will benefit in the long run from the real scale of the economic transformation driven by AI. NVDA’s Growth Drivers Despite Record Market Capitalization Nvidia’s strategy is b...

Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Ryerson Holding Corp (Symbol: RYZ) will trade ex-dividend, for its quarterly dividend of $0.1875, payable on 6/18/26. As a percentage of RYZ's recent stock price of $28.50, this dividend works out to app

格隆汇6月2日｜雅居乐集团公告，公司及其附属公司（集团）连同集团合营公司及联营公司以及由集团管理并以“雅居乐”品牌销售的房地产项目（雅居乐项目）于2026年5月的预售金额合计为约人民币6.5亿元而对应建筑面积为约5.8万平方米；平均价为每平方米人民币11,193元。截至2026年5月31日止五个月，集团连同集团合营公司及联营公司以及雅居乐项目的预售金额合计为约人民币29.8亿元而对应建筑面积为约28.1万平方米；平均价为每平方米人民币10,634元。

Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Liberty Energy Inc (Symbol: LBRT) will trade ex-dividend, for its quarterly dividend of $0.09, payable on 6/18/26. As a percentage of LBRT's recent stock price of $30.33, this dividend works out to appro

6月2日，中国工程院官网刊发了中国工程院院士杜祥琬的一则声明。杜祥琬表示，“近期，在网络上出现一些宣传，声称本人及其团队将核技术应用于垃圾焚烧，取得显著效果。本人与团队参与了‘无废城市’试点建设相关咨询项目研究。但本人从未参与，也未委托任何单位或个人将核技术应用于垃圾焚烧，当前网络流传的相关新闻报道内容均为不实信息。”他表示，现提醒各媒体及网络平台严格审核发布内容，本人将保留追究相关单位和个人法律责任的权利。（澎湃新闻）

康宝莱 公司周二宣布，首席财务官John DeSimone将于6月11日出席在东海岸举行的IDEAS会议并发表演讲。此次亮相正值这家营养品巨头完成多项战略布局、业绩持续改善的关键时期。 根据公司公告，DeSimone的演讲定于6月11日（周四）上午10时35分（美国东部时间）举行。投资者可通过康宝莱官网投资者关系页面观看现场网络直播，会议结束后回放将在网站上保留六个月。 此次会议召开之际，康宝莱正处于战略转型的加速期。公司5月发布的第一季度财报显示，净销售额达13亿美元，同比增长7.8%，超出此前指引；调整后EBITDA为1.757亿美元，同样超越预期。亚太和拉美市场表现强劲，分别增长17.3%和17.1%，但中国市场销售额同比下降12%，成为唯一连续下滑的核心市场。 在战略层面，康宝莱近期完成了多项关键布局。4月29日，公司完成14.5亿美元高级担保债务再融资，预计每年可节省约4500万美元利息支出。次日，康宝莱以5500万美元基础对价收购了英国个性化营养公司Bioniq的核心资产，并附加最高9500万美元的业绩对赌条款。Bioniq的个性化补充剂预计6月底起在11个欧洲国家上市，7月登陆美国。 此外，公司正推进全球产品包装重新设计，并推出个性化营养产品线。首席执行官Stephan Gratziani表示，公司正加速进化为“全球首屈一指的健康与健康平台”。 今年以来，康宝莱股价累计上涨约15%。分析师平均评级为“持有”，目标价约17美元。市场关注DeSimone届时是否会就Bioniq整合进展、中国区复苏策略及全年业绩指引提供更多细节。 责任编辑：张俊 SF065

Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Qualcomm Inc (Symbol: QCOM) will trade ex-dividend, for its quarterly dividend of $0.92, payable on 6/25/26. As a percentage of QCOM's recent stock price of $232.17, this dividend works out to approximat

Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Saratoga Investment Corp New (Symbol: SAR) will trade ex-dividend, for its monthly dividend of $0.25, payable on 6/23/26. As a percentage of SAR's recent stock price of $22.62, this dividend works out to

Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, SLM Corp. (Symbol: SLM) will trade ex-dividend, for its quarterly dividend of $0.13, payable on 6/15/26. As a percentage of SLM's recent stock price of $22.15, this dividend works out to approximately 0.

ORCL Maintains by Scotiabank -- Price Target Raised to $290 GuruFocus

南开大学生命科学院院长陈佺被免职，博士后郑浩被解聘；中山大学肿瘤防治中心实验研究部副主任康铁邦、生命科学学院副院长邝栋明被免职。《自然》系列期刊发言人表示，正在评估相关信息 2026年5月21日，“耿同学讲故事”账号。图：IC PHOTO 【财新网】 南开大学和中山大学近日分别公布涉学术不端调查结果，决定免去多位院长、副院长及研究部负责人职务。此前，自媒体科学博主“耿同学讲故事”（下称“耿同学”）连续公开举报多所高校学者发表于《自然》《科学》《细胞》等国际顶级学术期刊的论文存在图片和数据问题。 针对上述调查结果，《自然》系列期刊发言人回复财新称，已注意到有关机构调查结论，目前正在认真评估相关信息。 从3月底到4月初，“耿同学”制作发布了多期深度视频，指时任同济大学生命科学与技术学院院长王平、同济大学高等研究院研究员金佳丽2025年1月发表于《自然》杂志（Nature）上的一篇研究论文涉学术不端。作者团队将该论文称为“十年磨一剑”，然而“耿同学”的视频讲解了多位同行研究者对其的质疑，指该论文“冲击史上最假Nature”。

Key PointsCathie Wood's Ark Invest added to its Nvidia position for the first time in almost two weeks.

Berkshire Hathaway (NYSE: BRKA) (NYSE: BRKB) owns dozens of well-known businesses as well as a stock portfolio worth about $300 billion. But over the past few years, the biggest source of frustration among investors hasn't had anything to do with either of those things. It's the hundreds of billions of dollars in cash on Berkshire's balance sheet that is earning low-single-digit returns, while the S&P 500 has gained 15% or more in the typical year. It looks like Berkshire's new CEO, Greg Abel, is putting some of that to work. Berkshire has announced two major investments in just two days. And while by themselves, they aren't likely to be needle-movers, if this pattern continues, it could be a big deal for the company and its investors. Image source: Getty Images. Continue reading

ADragan/iStock via Getty Images Oculis Investment Overview The stock of Oculis Holding AG ( OCS ), a Zug, Switzerland headquartered biotech focused on the treatment of neuro-ophthalmic and ophthalmic diseases, was in freefall yesterday, dropping >35% for the day, from ~$23 per share to $15 per share, as the market digested topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema ("DME"), released late Friday. Oculis stock is now down >50% on a 5-day basis, and its market cap has fallen to ~$830m pre-market today. According to an Oculis press release : The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consisted of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52 weeks of treatment. Over 800 patients were enrolled across both pivotal trials at 119 investigational sites throughout the United States and several other countries. The primary endpoint, mean change in best corrected visual acuity early treatment diabetic retinopathy study ("BCVA ETDRS") letter score at Week 52, was not met in both trials. The secondary endpoint of retinal thickness, as measured by OCT, showed a substantial and persistent reduction with OCS-01 vs vehicle at all visits in DIAMOND-2 and at all visits except Week 52 in DIAMOND-1. The key secondary endpoint of the proportion of patients with ≥15-letter gain in BCVA was not met in both trials. Oculis had formerly communicated that if results from the studies were positive, it would submit a New Drug Application requesting an FDA approval for OCS-01 by the end of this year, but in Friday's press release, a statement reads: Based on the results, at this time, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in DME Analysis - Significant Miss Scuppers Innovative Therapies' Approval Shot Biotech companies are often unwilling to give up on a lead asset ev...